GLP-1 Compounding: Court Backs US FDA Approach To Managing Drug Shortage List

 
• By Sue Sutter

A lengthy notice-and-comment rulemaking process is not congruent with the congressional mandate to keep an up-to-date list of drugs in short supply, US judge said, denying compounders' request to stay removal of the GLP-1 tirzepatide from the shortage list.

MIsaligned pencils
A court said the notice-and-comment rulemaking process is not aligned with Congress' mandate that the FDA keep an up-to-date list of drugs in shortage. (Shutterstock)

More from Litigation

More from Legal & IP